Resultados da busca - Xiaodan Lai

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system por Rui Xiong, Jing Lei, Sicen Pan, Hong Zhang, Yongtao Tong, Wei Wu, Yi Huang, Xiaodan Lai

Connect to this object online.

Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example por Rui Xiong, Jing Lei, Lu Wang, Shipeng Zhang, Hengxu Liu, Hongping Wang, Tao Liu, Xiaodan Lai

Connect to this object online.